4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
9.46
+0.01 (0.11%)
At close: Apr 28, 2026, 4:00 PM EDT
9.42
-0.04 (-0.42%)
After-hours: Apr 28, 2026, 4:10 PM EDT
4D Molecular Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 85.21 | 0.04 | 20.72 | 3.13 | 18.04 | |
| Revenue Growth (YoY) | 230194.59% | -99.82% | 562.29% | -82.65% | 32.52% | |
| Cost of Revenue | 192.5 | 141.3 | 97.1 | 80.25 | 61.36 | |
| Gross Profit | -107.29 | -141.26 | -76.37 | -77.12 | -43.32 | |
| Selling, General & Admin | 49.06 | 46.58 | 36.49 | 32.91 | 28.01 | |
| Operating Expenses | 49.06 | 46.58 | 36.49 | 32.91 | 28.01 | |
| Operating Income | -156.35 | -187.84 | -112.87 | -110.03 | -71.33 | |
| Interest & Investment Income | 19.48 | 27.05 | 12.21 | 2.57 | 0.14 | |
| Other Non Operating Income (Expenses) | -0.04 | -0.08 | -0.18 | -0.04 | -0.12 | |
| EBT Excluding Unusual Items | -136.91 | -160.87 | -100.84 | -107.49 | -71.32 | |
| Merger & Restructuring Charges | -3.2 | - | - | - | - | |
| Pretax Income | -140.11 | -160.87 | -100.84 | -107.49 | -71.32 | |
| Net Income | -140.11 | -160.87 | -100.84 | -107.49 | -71.32 | |
| Net Income to Common | -140.11 | -160.87 | -100.84 | -107.49 | -71.32 | |
| Shares Outstanding (Basic) | 58 | 54 | 39 | 32 | 28 | |
| Shares Outstanding (Diluted) | 58 | 54 | 39 | 32 | 28 | |
| Shares Change (YoY) | 7.39% | 37.86% | 20.95% | 16.66% | 331.23% | |
| EPS (Basic) | -2.42 | -2.98 | -2.58 | -3.32 | -2.57 | |
| EPS (Diluted) | -2.42 | -2.98 | -2.58 | -3.32 | -2.57 | |
| Free Cash Flow | -109.62 | -138.37 | -78.56 | -98.22 | -78.24 | |
| Free Cash Flow Per Share | -1.89 | -2.56 | -2.01 | -3.04 | -2.82 | |
| Gross Margin | -125.91% | - | - | - | -240.17% | |
| Operating Margin | -183.49% | -507678.38% | -544.65% | -3516.52% | -395.46% | |
| Profit Margin | -164.43% | -434778.38% | -486.59% | -3435.41% | -395.37% | |
| Free Cash Flow Margin | -128.65% | -373975.68% | -379.11% | -3139.05% | -433.77% | |
| EBITDA | -151.65 | -183.19 | -108.66 | -107.63 | -69.81 | |
| EBITDA Margin | -177.98% | - | - | - | - | |
| D&A For EBITDA | 4.69 | 4.65 | 4.2 | 2.4 | 1.52 | |
| EBIT | -156.35 | -187.84 | -112.87 | -110.03 | -71.33 | |
| EBIT Margin | -183.49% | - | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.